TY - JOUR
T1 - Antibody response to COVID-19 vaccine in 130 recipients of hematopoietic stem cell transplantation
AU - Tsushima, Takafumi
AU - Terao, Toshiki
AU - Narita, Kentaro
AU - Fukumoto, Ami
AU - Ikeda, Daisuke
AU - Kamura, Yuya
AU - Kuzume, Ayumi
AU - Tabata, Rikako
AU - Miura, Daisuke
AU - Takeuchi, Masami
AU - Matsue, Kosei
N1 - Funding Information:
The authors would like to thank the patients with hematologic malignancy, their families, the age-adjusted patients, and the medical staff of the Department of Hematology of Kameda Medical Center. We also would like to thank Ms. Eri Suzuki for her secretarial assitance. We also thank Editage (https://www.editage.jp/ ) for English language editing.
Publisher Copyright:
© 2022, Japanese Society of Hematology.
PY - 2022/5
Y1 - 2022/5
N2 - We evaluated anti-spike protein antibody (anti-S) production in 130 hematopoietic stem cell transplant (HSCT) recipients who received the coronavirus disease-2019 vaccine. Sixty-five received allo-HSCT and 65 received auto-HSCT. Disease-specific treatments were being administered to 43.1% of allo-HSCT and 69.2% of auto-HSCT patients. Seropositivity was observed in 87.7% of allo-HSCT and 89.2% in auto-HSCT patients. Anti-S antibody production was significantly impaired in auto-HSCT patients compared with controls (178U/mL [0.4–4990.0] vs. 669 U/mL [40.3–4377.0], p < 0.001), but not in allo-HSCT patients (900 U/mL [0.4–12,893.0] vs. 860 U/mL [40.3–8988.0], P = 0.659). Clinically relevant anti-S antibody levels (> 264 U/mL) were achieved in 59.2% of patients (76.9% in allo-HSCT and 41.5% in auto-HSCT). The main factors influencing the protective level of the antibody response were the CD19 + cell count and serum immunoglobulin G levels, and these were significant in both allo-HSCT and auto-HSCT patients. Other factors included time since HSCT, complete remission status, use of immunosuppressive drugs, and levels of lymphocyte subsets including CD4, CD8 and CD56 positive cells, but these were only significant in allo-HSCT patients. Allo-HSCT patients had a relatively favorable antibody response, while auto-HSCT patients had poorer results.
AB - We evaluated anti-spike protein antibody (anti-S) production in 130 hematopoietic stem cell transplant (HSCT) recipients who received the coronavirus disease-2019 vaccine. Sixty-five received allo-HSCT and 65 received auto-HSCT. Disease-specific treatments were being administered to 43.1% of allo-HSCT and 69.2% of auto-HSCT patients. Seropositivity was observed in 87.7% of allo-HSCT and 89.2% in auto-HSCT patients. Anti-S antibody production was significantly impaired in auto-HSCT patients compared with controls (178U/mL [0.4–4990.0] vs. 669 U/mL [40.3–4377.0], p < 0.001), but not in allo-HSCT patients (900 U/mL [0.4–12,893.0] vs. 860 U/mL [40.3–8988.0], P = 0.659). Clinically relevant anti-S antibody levels (> 264 U/mL) were achieved in 59.2% of patients (76.9% in allo-HSCT and 41.5% in auto-HSCT). The main factors influencing the protective level of the antibody response were the CD19 + cell count and serum immunoglobulin G levels, and these were significant in both allo-HSCT and auto-HSCT patients. Other factors included time since HSCT, complete remission status, use of immunosuppressive drugs, and levels of lymphocyte subsets including CD4, CD8 and CD56 positive cells, but these were only significant in allo-HSCT patients. Allo-HSCT patients had a relatively favorable antibody response, while auto-HSCT patients had poorer results.
KW - Allogeneic HSCT
KW - Antibody
KW - Autologous HSCT
KW - COVID-19 vaccine
UR - http://www.scopus.com/inward/record.url?scp=85128187293&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85128187293&partnerID=8YFLogxK
U2 - 10.1007/s12185-022-03325-9
DO - 10.1007/s12185-022-03325-9
M3 - Article
C2 - 35426579
AN - SCOPUS:85128187293
SN - 0925-5710
VL - 115
SP - 611
EP - 615
JO - International journal of hematology
JF - International journal of hematology
IS - 5
ER -
